About 100 reports

  • 2 Type 2 Diabetes (T2D): Executive Summary
  • 12.1 BIBLIOGRAPHY

THE SAFETY AND TOLERABILITY OF GLP-## RECEPTOR AGONISTS IN THE TREATMENT OF TYPE ## DIABETES: A REVIEW.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, 2016 and 2026
  • 2.1 RELATED REPORTS

Comparison of the prevalence of chronic kidney disease in Japanese patients with type ## and type ## diabetes.

  • Type 2 Diabetes
  • Germany
  • United States
  • World
  • Forecast
  • DEFRONZO RA, ET AL. (2014). NOVEL AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES. DIABETES SPECTRUM; 27: 100-112
  • VAN AMBURGH JA (2015). WHY SELECT EXTENDED-RELEASE METFORMIN? MEDSCAPE MULTISPECIALTY. AVAILABLE FROM: HTTP://WWW.MEDSCAPE.COM/VIEWARTICLE/845753 [ACCESSED ON JUNE 7, 2017]

GENETICS OF TYPE ## DIABETES.

  • Type 2 Diabetes
  • Market Size
  • AstraZeneca PLC
  • Novo Nordisk Group
  • Sanofi S.A.
  • Type 2 Diabetes Development Stages for Pipeline Drugs
  • Top Targets for Pipeline Drug Development Against Type 2 Diabetes

Type ## Diabetes: Competitive Landscape to 2026 Report Code: GDHC##CL Published: March 2018 Healthcare TABLE OF CONTENTS ##.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • France
  • United States
  • World
  • Forecast
  • FEATURES OF TYPE 2 DIABETES MELLITUS PATIENTS
  • Netherlands Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)

Current Prevalence of Type ## and Type ## diabetes in adults and children in the UK.

  • Type 2 Diabetes
  • East Asia
  • North America
  • Northern Europe
  • Scandinavia

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • United States
  • Market Shares
  • Market Size

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 2 Diabetes
  • Europe
  • France
  • Germany
  • Forecast
  • TYPE 2 DIABETES DRUGS MARKET IN APAC
  • TYPE 2 DIABETES DRUGS MARKET IN AMERICAS

It is indicated for the treatment of type ## and type ## diabetes mellitus.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 2 Diabetes
  • France
  • Germany
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Japan
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United States
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • United Kingdom
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Italy
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Germany
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • France
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • Spain
  • Market Size

FIGURE ##-##: ACELITY L. P.

  • Type 2 Diabetes
  • World
  • Acelity L.P. Inc.
  • Coloplast Group
  • Derma Sciences, Inc.
  • 4.3 ETIOLOGY AND PATHOPHYSIOLOGY
  • Case Flow Map

PREVALENCE OF TYPE ## AND TYPE ## DIABETES AMONG CHILDREN AND ADOLESCENTS FROM 2001 TO 2009.

  • Type 2 Diabetes
  • Forecast
  • Daiichi Sankyo Company
  • Depomed, Inc.
  • Pfizer Inc.
  • KOL Profile: Dennis Andress, Clinical Trials
  • 8.5.3. KOL PROFILE: GLENN CHERTOW

DIABETES-TRIGGERED KIDNEY DISEASE HAS BEEN OBSERVED TO BE MORE COMMON AMONG TYPE ## DIABETICS; HOWEVER, SINCE THE PATIENT POPULATION FOR TYPE ## DIABETES IS HIGHER, THE NUMBER OF INDIVIDUALS WITH THE LATTER CONDITION SUFFERING FROM CKD IS HIGHER.

  • Type 2 Diabetes
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Resverlogix Corp.
  • Vifor Pharma
  • 5.3 GLOBAL AND HISTORICAL TRENDS
  • MM, DIAGNOSED PREVALENCE OF DME IN THE DIAGNOSED DIABETIC RETINOPATHY POPULATION,

The upsurge in DME prevalence will be driven by the US and ##EU, where it is expected to increase at a CAGR of ##% directly following the increases expected for type ## and type ## diabetes.

  • Type 2 Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Drug Overview: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Analysis: Invokana TABLE OF CONTENTS ## Product Profiles ## Invokana : Diabetic nephropathy ## Invokana : Diabetes type ## LIST OF FIGURES ## Figure ##: Invokana for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary for Invokana in d

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug analysis: Farxiga

8770 10000 7800

Drug analysis: Farxiga PRODUCT PROFILES Farxiga : Diabetes type ## Farxiga : Diabetes type ## LIST OF FIGURES Figure ##: Farxiga for type ## diabetes – SWOT analysis Figure ##: Datamonitor Healthcare drug assessment of Farxiga Figure ##: Datamonitor Healthcare drug assessment s

  • Diabetes
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Overview: Farxiga

8770 10000 7800

Drug Overview: Farxiga TABLE OF CONTENTS ## Product Profiles ## Farxiga : Diabetic nephropathy ## Farxiga : Diabetes type ## ## Farxiga : Chronic heart failure (CHF) ## Farxiga : Diabetes type ## LIST OF FIGURES ## Figure ##: Farxiga for diabetic nephropathy – SWOT analysis ## Figure

  • Chronic Disease
  • Type 2 Diabetes
  • European Union
  • Japan
  • United States

Drug Analysis: Jardiance TABLE OF CONTENTS & nbsp; ## Product Profiles ## Jardiance : Diabetic nephropathy ## Jardiance : Chronic heart failure (CHF) ## Jardiance : Diabetes type ## LIST OF FIGURES ## Figure ##: Jardiance for diabetic nephropathy – SWOT analysis ## Figure ##: Datamoni

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Drug Overview: Jardiance TABLE OF CONTENTS ## Product Profiles ## Jardiance : Diabetic nephropathy ## Jardiance : Chronic heart failure (CHF) ## Jardiance : Diabetes type ## LIST OF FIGURES ## Figure ##: Jardiance for diabetic nephropathy – SWOT analysis ## Figure ##: Datamonitor Health

  • Type 2 Diabetes
  • European Union
  • Japan
  • United States
  • Demand

Market Overview Increasing incidence of diabetic nephropathy among diabetic patients The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type ## diabetes patients.

  • Chronic Disease
  • Pathology
  • Type 2 Diabetes
  • World
  • Social Conditions
  • TYPE 2 DIABETES GENE THERAPY
  • TYPE 2 DIABETES RNA BASED THERPY

THE MAJOR TARGETS FOR TYPE ## DIABETES INCLUDES GLP-## AGONIST AND GLP-## & GCGR AGONISTS.

  • Type 2 Diabetes
  • United States
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • MM, Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population, 2016
  • 3.2 RISK FACTORS AND COMORBIDITIES

sequence=##.

  • Type 2 Diabetes
  • Germany
  • Spain
  • United States
  • Forecast